These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 9295513)

  • 41. Randomized trial of drip infusion versus bolus injection of vinorelbine for the control of local venous toxicity.
    Yoh K; Niho S; Goto K; Ohmatsu H; Kubota K; Kakinuma R; Saijo N; Nishiwaki Y
    Lung Cancer; 2007 Mar; 55(3):337-41. PubMed ID: 17126951
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Addition of PTK787/ZK 222584 can lower the dosage of amsacrine to achieve equal amounts of acute myeloid leukemia cell death.
    Weidenaar AC; de Jonge HJ; Fidler V; ter Elst A; Meeuwsen-de Boer T; Douwes J; Bouma-ter Steege JC; Hählen K; Kamps WA; de Bont ES
    Anticancer Drugs; 2008 Jan; 19(1):45-54. PubMed ID: 18043129
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
    Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of cellular ATP depletion on topoisomerase II poisons. Abrogation Of cleavable-complex formation by etoposide but not by amsacrine.
    Sorensen M; Sehested M; Jensen PB
    Mol Pharmacol; 1999 Mar; 55(3):424-31. PubMed ID: 10051525
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Amsacrine containing induction therapy in elderly AML patients: comparison to standard induction regimens in a matched-pair analysis.
    Kessler T; Mohr M; Müller-Tidow C; Krug U; Brunnberg U; Mohr B; Schliemann C; Sauerland C; Serve H; Büchner T; Berdel WE; Mesters RM
    Leuk Res; 2008 Mar; 32(3):491-4. PubMed ID: 17675230
    [TBL] [Abstract][Full Text] [Related]  

  • 46. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.
    Yavuz S; Paydas S; Disel U; Sahin B
    Am J Ther; 2006; 13(5):389-93. PubMed ID: 16988532
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Determination of amsacrine in human nucleated hematopoietic cells.
    Brons PP; Wessels JM; Linssen PC; Haanen C; Speth PA
    J Chromatogr; 1987 Nov; 422():175-85. PubMed ID: 2449448
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Blast cell-surface and plasma soluble urokinase receptor in acute leukemia patients: relationship to classification and response to therapy.
    Mustjoki S; Alitalo R; Stephens RW; Vaheri A
    Thromb Haemost; 1999 May; 81(5):705-10. PubMed ID: 10365741
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The function of the immune system after the treatment of pediatric malignant diseases].
    Gadó J; Schlick B; Bárány O; Németh J; Müller J; Csóka M; Constantin T; Vonnák E; Böcskei R; Hauser P; Kovács G
    Orv Hetil; 2006 Sep; 147(36):1731-8. PubMed ID: 17087017
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Level of tau protein in children treated for acute lymphoblastic leukemia.
    Muszyńska-Rosłan K; Krawczuk-Rybak M; Protas PT; Hołownia A
    Pediatr Neurol; 2006 May; 34(5):367-71. PubMed ID: 16647996
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children.
    Horstmann MA; Hassenpflug WA; zur Stadt U; Escherich G; Janka G; Kabisch H
    Haematologica; 2005 Dec; 90(12):1701-3. PubMed ID: 16330449
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recurrent infusion phlebitis induced by cyclosporine.
    Rottenberg Y; Fridlender ZG
    Ann Pharmacother; 2004 Dec; 38(12):2071-3. PubMed ID: 15507500
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Advances in therapy of multiple myeloma: lessons from acute leukemia.
    Barlogie B
    Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2605-13. PubMed ID: 10068262
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Neutropenic enterocolitis: a serious complication during the treatment of acute leukemias.
    Wach M; Dmoszynska A; Wasik-Szczepanek E; Pozarowski A; Drop A; Szczepanek D
    Ann Hematol; 2004 Aug; 83(8):522-6. PubMed ID: 14658010
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.
    Schmid C; Schleuning M; Ledderose G; Tischer J; Kolb HJ
    J Clin Oncol; 2005 Aug; 23(24):5675-87. PubMed ID: 16110027
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The use of multilumen catheters in acute leukemia patients.
    Hughes CB; Bryant JK
    NITA; 1984; 7(6):484-6. PubMed ID: 6568461
    [No Abstract]   [Full Text] [Related]  

  • 57. Allogeneic and autologous bone marrow transplantation after consolidation therapy in high-risk acute myeloid leukemia in children. Towards a risk-oriented therapy.
    Ortega JJ; Díaz de Heredia C; Olivé T; Bastida P; Llort A; Armadans L; Torrabadella M; Massuet L
    Haematologica; 2003 Mar; 88(3):290-9. PubMed ID: 12651268
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Treatment strategies for childhood acute leukemia and their effectiveness: message to internists from a pediatrician].
    Hujimoto T
    Rinsho Ketsueki; 1999 Apr; 40(4):255-61. PubMed ID: 10355130
    [No Abstract]   [Full Text] [Related]  

  • 59. [Therapy-induced leukemia -- an underestimated complication of antineoplastic chemotherapy?].
    Dührsen U
    Zentralbl Gynakol; 2005 Aug; 127(4):235-41. PubMed ID: 16037905
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells.
    Jensen LH; Dejligbjerg M; Hansen LT; Grauslund M; Jensen PB; Sehested M
    BMC Pharmacol; 2004 Dec; 4():31. PubMed ID: 15575955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.